• Login
    View Item 
    •   Home
    • 1 Published Research and Commentary
    • Trypanosomiasis/Sleeping Sickness
    • View Item
    •   Home
    • 1 Published Research and Commentary
    • Trypanosomiasis/Sleeping Sickness
    • View Item
    Feb 24, 2021
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of MSFTitleAuthorsSubjectsPublisherJournalThis CollectionTitleAuthorsSubjectsPublisherJournal

    Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    combination trypano.pdf
    Size:
    235.5Kb
    Format:
    PDF
    Download
    Authors
    Priotto, G
    Fogg, C
    Balasegaram, M
    Erphas, O
    Louga, A
    Checchi, F
    Ghabri, S
    Piola, P
    Affiliation
    gpriotto@epicentre.msf.org
    Issue Date
    2006
    
    Metadata
    Show full item record
    Journal
    PLoS Clinical Trials
    Abstract
    OBJECTIVES: Our objective was to compare the efficacy and safety of three drug combinations for the treatment of late-stage human African trypanosomiasis caused by Trypanosoma brucei gambiense. DESIGN: This trial was a randomized, open-label, active control, parallel clinical trial comparing three arms. SETTING: The study took place at the Sleeping Sickness Treatment Center run by Médecins Sans Frontières at Omugo, Arua District, Uganda PARTICIPANTS: Stage 2 patients diagnosed in Northern Uganda were screened for inclusion and a total of 54 selected. INTERVENTIONS: Three drug combinations were given to randomly assigned patients: melarsoprol-nifurtimox (M+N), melarsoprol-eflornithine (M+E), and nifurtimox-eflornithine (N+E). Dosages were uniform: intravenous (IV) melarsoprol 1.8 mg/kg/d, daily for 10 d; IV eflornithine 400 mg/kg/d, every 6 h for 7 d; oral nifurtimox 15 (adults) or 20 (children <15 y) mg/kg/d, every 8 h for 10 d. Patients were followed up for 24 mo. OUTCOME MEASURES: Outcomes were cure rates and adverse events attributable to treatment. RESULTS: Randomization was performed on 54 patients before enrollment was suspended due to unacceptable toxicity in one of the three arms. Cure rates obtained with the intention to treat analysis were M+N 44.4%, M+E 78.9%, and N+E 94.1%, and were significantly higher with N+E (p = 0.003) and M+E (p = 0.045) than with M+N. Adverse events were less frequent and less severe with N+E, resulting in fewer treatment interruptions and no fatalities. Four patients died who were taking melarsoprol-nifurtimox and one who was taking melarsoprol-eflornithine. CONCLUSIONS: The N+E combination appears to be a promising first-line therapy that may improve treatment of sleeping sickness, although the results from this interrupted study do not permit conclusive interpretations. Larger studies are needed to continue the evaluation of this drug combination in the treatment of T. b. gambiense sleeping sickness.
    URI
    http://hdl.handle.net/10144/18264
    DOI
    10.1371/journal.pctr.0010039
    PubMed ID
    17160135
    Language
    en
    ISSN
    1555-5887
    ae974a485f413a2113503eed53cd6c53
    10.1371/journal.pctr.0010039
    Scopus Count
    Collections
    Trypanosomiasis/Sleeping Sickness

    entitlement

     
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.